Welcome and Introduction
Real-world Cases and Panel Discussion
- Biology, clinical presentation, and diagnostic approach for AL amyloidosis
- Current/evolving management algorithm for the patient with newly diagnosed AL amyloidosis
- Treatment response assessment; hematologic/organ response criteria
- Current/evolving algorithm for the management of AL amyloidosis at relapse
- Supportive management in AL amyloidosis
- Common pitfalls in the management of patients with AL amyloidosis
Audience Question and Answer Session
Date / Time
New Orleans, LA
Hyatt Regency New Orleans
Jeffrey Zonder, MD
Associate Professor of Oncology and Medicine
Barbara Ann Karmanos Cancer Institute
Wayne State University School of Medicine
The goal of this activity is to improve the knowledge, competence, and performance of learners in using novel therapeutic options for patients with AL amyloidosis.
This program is intended for physicians and other healthcare professionals who care for patients with AL amyloidosis.
Upon completion of this activity, participants should be able to:
- Diagnose AL amyloidosis through timely and accurate typing of the precursor protein to guide specific management approaches
- Integrate into practice up-to-date efficacy and safety data on currently available and novel regimens to treat newly diagnosed and relapsed/refractory AL amyloidosis based on accurate risk and response assessment
- Plan evidence-based supportive therapy in AL amyloidosis to improve quality of life, relieve symptoms, and sustain organ function
- Identify patients appropriate for enrollment on ongoing clinical trials evaluating novel therapy for the treatment of patients with AL amyloidosis
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.